An interventional study of HR-MRI and Standard CT Imaging in Mesothelioma and Peritoneal Mesothelioma, sponsored by University of Chicago. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by University of Chicago · Not applicable, Interventional, and Screening
For cancers, such as mesothelioma, that spread to the lining of the stomach, detecting the cancer is very difficult with CT or MRI scans. Researchers at the University of Chicago want to find out if the new experimental MRI and ultrasound imaging techniques do a better job of detecting these cancers. Researchers will use new MRI and ultrasound techniques to see if it can find evidence of cancer that has spread to the lining of the abdomen, and right now these new techniques are only used for research.
475 studies on the registry are indexed under Mesothelioma; 75 are open to participants now.
This study's enrollment of 26 is below the median of 40 across 376 interventional studies indexed under Mesothelioma.
Browse Mesothelioma studies →University of Chicago is the lead sponsor of 924 studies on the registry; 186 are open to participants now.
Of its 102 completed or terminated interventional studies of FDA-regulated products, 71 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The goal is to test several different novel Magnetic Resonance sequences to determine which gives the best visualization of peritoneal disease.
Diagnostic Test: HR-MRI · Diagnostic Test: Standard CT Imaging
Patients will undergo conventional and HR-MRI imaging as well as abdominal ultrasound to define the performance of these methods.
Diagnostic Test: HR-MRI · Diagnostic Test: Ultrasound
The first 5 patients will undergo HR-MRI scans using different sequence parameters. Results in these patients will then be assessed along with standard CT Imaging to determine which sequences appear to best identify peritoneal disease. The optimal HR-MRI sequences will then be used for the next 19 patients in the Testing phase to formally define their performance compared to standard imaging.
Standard CT scans will be performed for preoperative imaging in all patients.
Ultrasound Elastography will be performed using an FDA-Approved diagnostic GE ultrasound scanner
Higher Sensitivity for detection using New High Resolution Contrast Enhanced MRI Imaging Sequences compared to standard MRI
New HR-MRI sequences will demonstrate greater sensitivity than standard MRI for detecting peritoneal metastases.
Time frame: 60 Days
Higher sensitivity for detection of peritoneal metastatic disease using Ultrasound Elastography compared to standard MRI
Ultrasound Elastography will demonstrate greater sensitivity than standard MRI for detecting peritoneal metastases.
Time frame: 60 Days
The performance of diffusion-weighted MRI in detecting peritoneal disease in patients with malignant peritoneal mesothelioma
Use diffusion-weighted MRI in detecting the per-region sensitivity in patients with MPM
Time frame: 60 days
Test high-definition small-voxel MRI imaging sequences for detection of peritoneal disease in MPM
To test HR-MRI sequences for detection of peritoneal disease in MPM focusing on the right hemidiaphragmatic and pelvic spaces
Time frame: 60 days
Perform Ultrasound Elastography in peritoneal mesothelioma to determine optimal strain ratios
Ultrasound Elastography to determine optimal strain ratios to maximize sensitivity in PM patients
Time frame: 60 days
Perform Ultrasound Elastography in peritoneal mesothelioma to determine elasticity scores
Ultrasound Elastography to determine elasticity scores to maximize sensitivity in PM patients
Time frame: 60 days
Ran from Oct 2018 to primary completion in Jul 2022, 45 months.
Of 21 interventional studies with no phase under Mesothelioma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 141. This study's 45 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.